These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

27 related items for PubMed ID: 15915011

  • 1. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ, Houghton CM, Singh SD.
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [Abstract] [Full Text] [Related]

  • 2. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
    Tomlinson HS, Corlett SA, Allen MB, Chrystyn H.
    Br J Clin Pharmacol; 2005 Dec; 60(6):605-10. PubMed ID: 16305584
    [Abstract] [Full Text] [Related]

  • 3. Techniques of assessing small airways dysfunction.
    McNulty W, Usmani OS.
    Eur Clin Respir J; 2014 Dec; 1():. PubMed ID: 26557240
    [Abstract] [Full Text] [Related]

  • 4. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ, Houghton CM, Singh SD.
    Respiration; 2005 Dec; 72 Suppl 1():35-7. PubMed ID: 15915011
    [Abstract] [Full Text] [Related]

  • 5. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A.
    Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Oct; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 7. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
    Respiration; 2005 Oct; 72 Suppl 1():20-7. PubMed ID: 15915009
    [Abstract] [Full Text] [Related]

  • 8. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE, Noonan MJ.
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [Abstract] [Full Text] [Related]

  • 9. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
    Hendeles L, Colice GL, Meyer RJ.
    N Engl J Med; 2007 Mar 29; 356(13):1344-51. PubMed ID: 17392304
    [No Abstract] [Full Text] [Related]

  • 10. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ, Houghton CM, Singh SD.
    Respiration; 2005 Mar 29; 72 Suppl 1():35-7. PubMed ID: 15915011
    [Abstract] [Full Text] [Related]

  • 11. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
    Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A.
    Br J Clin Pharmacol; 2004 Oct 29; 58(4):359-66. PubMed ID: 15373928
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Oct 29; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
    Respiration; 2005 Oct 29; 72 Suppl 1():20-7. PubMed ID: 15915009
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G.
    Respiration; 2005 Oct 29; 72 Suppl 1():6-12. PubMed ID: 15915007
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Oct 29; 72 Suppl 1():13-9. PubMed ID: 15915008
    [Abstract] [Full Text] [Related]

  • 16. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ, Houghton CM, Singh SD.
    Respiration; 2005 Oct 29; 72 Suppl 1():35-7. PubMed ID: 15915011
    [Abstract] [Full Text] [Related]

  • 17. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE, Noonan MJ.
    J Asthma; 2010 May 29; 47(4):447-59. PubMed ID: 20528601
    [Abstract] [Full Text] [Related]

  • 18. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
    Hendeles L, Colice GL, Meyer RJ.
    N Engl J Med; 2007 Mar 29; 356(13):1344-51. PubMed ID: 17392304
    [No Abstract] [Full Text] [Related]

  • 19. Long-acting inhaled beta 2-agonists and the loss of "bronchoprotective" efficacy.
    Abisheganaden J, Boushey HA.
    Am J Med; 1998 May 29; 104(5):494-7. PubMed ID: 9626035
    [No Abstract] [Full Text] [Related]

  • 20. The rejuvenated pressurised metered dose inhaler.
    Bell J, Newman S.
    Expert Opin Drug Deliv; 2007 May 29; 4(3):215-34. PubMed ID: 17489650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 2.